Changes in Hong Kong stocks | Yiming Onko-B (01541) rose nearly 12%, and the company's cash reserves remained abundant, and many key clinical trials reached important points

The Zhitong Finance App learned that Yiming Onko-B (01541) surged nearly 12%. As of press release, it had risen 10.41% to HK$4.085, with a turnover of HK$3.49,000.

According to the news, on the evening of August 26, Yiming Enke announced its 2026 interim results. In the first half of this year, the company achieved revenue of 254.24 million yuan, mainly from payments collected through licensing and cooperation agreements with Axion Bio. The company's cash reserves remain strong. As of June 30, 2026, the company's cash and cash equivalents, financial assets measured at fair value, and term deposits with an original maturity date of more than three months totaled approximately $947 million.

During the reporting period, the company continued to rapidly advance the development of drug pipelines, and achieved important milestones and achievements in the fields of tumor immunotherapy and autoimmune diseases. Major clinical-stage assets such as IMM01 (tidapecip), IMM0306 (amurefurop α), and IMM2510 (pervilafp α) have made significant progress, and a number of key clinical trials have reached important milestones. At the same time, the company is actively expanding the field of non-tumor treatment, making significant progress in autoimmune diseases, metabolic diseases, cardiovascular diseases and pulmonary hypertension, further unleashing the therapeutic potential of drug candidates.